Ubs Asset Management Americas Inc Cassava Sciences Inc Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 60,894 shares of SAVA stock, worth $146,145. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,894
Previous 73,969
17.68%
Holding current value
$146,145
Previous $913,000
96.28%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding SAVA
# of Institutions
207Shares Held
14MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$7.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$6.05 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$2.79 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.42 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$1.39 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $96.2M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...